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randomized controlled trial to evaluate the
efficacy and feasibility of an individually tailored
home-based exercise training program for
children and adolescents with juvenile
dermatomyositis
Esther A Habers1, Marco van Brussel1*, Anneli C Langbroek-Amersfoort1,2, Annet van Royen-Kerkhof3
and Tim Takken1Abstract
Background: Juvenile dermatomyositis (JDM) is a rare, often chronic, systemic autoimmune disease of childhood,
characterized by inflammation of the microvasculature of the skeletal muscle and skin. Prominent clinical features
include significant exercise intolerance, muscle weakness, and fatigue. Despite pharmacological improvements,
these clinical features continue to affect patients with JDM, even when the disease is in remission. Exercise training
is increasingly utilized as a non-pharmacological intervention in the clinical management of (adult) patients with
chronic inflammatory conditions; however no randomized controlled trials (RCT) have been performed in JDM. In
the current study, the efficacy and feasibility of an exercise training program in patients with JDM will be examined.
Methods/design: Subjects (n= 30) will include 8–18 year olds diagnosed with JDM. The intervention consists of an
individually tailored 12-weeks home-based exercise training program in which interval training on a treadmill is
alternated with strength training during each session. The program is based on previous literature and designed
with a defined frequency, intensity, time, and type of exercise (FITT principles). Primary outcome measures include
aerobic exercise capacity, isometric muscle strength, and perception of fatigue. The study methodology has been
conceived according to the standards of the CONSORT guidelines. The current study will be a multi-center (4 Dutch
University Medical Centers) RCT, with the control group also entering the training arm directly after completion of
the initial protocol. Randomization is stratified according to age and gender.
Discussion: The current study will provide evidence on the efficacy and feasibility of an individually tailored 12-week
home-based exercise training program in youth with JDM.
Trial registration: Medical Ethics Committee of the University Medical Center Utrecht, the Netherlands: 11–336;
Netherlands Trial Register (NTR): NTR 3184.
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The pediatric forms of inflammatory idiopathic myop-
athies (IIM) embody a group of rare systemic autoimmune
conditions, characterized by chronic skeletal muscle in-
flammation with an age of onset of <18 years. Despite
being a rare condition, juvenile dermatomyositis (JDM) is
the most common type of pediatric IIM, representing
about 85% of IIM diagnoses in childhood [1]. JDM is char-
acterized by inflammation of the microvasculature of the
skeletal muscle and skin. While the etiology of the disease
remains largely unknown, environmental and genetic fac-
tors are thought to play a role in its development [2].
Prominent clinical features are significant muscle weak-
ness [3], anaerobic- and aerobic exercise intolerance [4-8],
and fatigue [9]. Furthermore, the patients show a skin rash
commonly seen on the face and extremities [10]. Less
frequently, the gastrointestinal tract, lungs, heart, and
rarely the central nervous system may also be involved
[10-12]. Despite pharmacological improvements, these
clinical features are persistently experienced in patients
with JDM, even when the disease is in remission [12-14].
Exercise training is increasingly utilized as a non-
pharmacological intervention in the clinical management
of patients with chronic inflammatory conditions. As
opposed to typically developing healthy children, those
with chronic illness are often restricted in their partici-
pation in physical activity as a consequence of real or
perceived limitations imposed by their condition. The
chronic condition itself often causes hypoactivity leading
to a deconditioning effect and a reduction in functional
ability, which ultimately results in a downward spiral of
further hypoactivity and deteriorating health [15]. Fur-
ther, children who are hypoactive are also thought to be
at high risk of developing a number of secondary health
complications commonly associated with a sedentary
lifestyle including cardiovascular disease, obesity, and
pre-diabetes [15]. Exercise training might prevent or
slow down the deconditioning as a result of hypoactivity,
but it might also reduce the systemic inflammation. To
date, very little is known about the effects of exercise
training in chronic pediatric conditions, including JDM.
In fact, only one study has examined the effect of exer-
cise training in one child with JDM in remission. Omori
et al. reported improvements in muscle strength, aerobic
exercise capacity, and muscle function in this child after
completing a 16-week exercise training program [16]. In
adults with active as well as inactive stable dermatomyo-
sitis, exercise training has been shown to improve aer-
obic exercise capacity, muscle strength, functional ability,
fatigue, and health status [17]. These improvements may
theoretically be explained by the role of chronic exercise
in inducing changes at the origins of the observed exer-
cise intolerance, which include decreased capillary dens-
ity, perivascular atrophy of type I and II muscle fibers,and reduction of key enzymes essential for producing
ATP [18].
Studies in patients with adult and juvenile dermato-
myositis suggest that exercise training is safe since it has
not been associated with any increases in the degree of
inflammation after a single bout of exercise in JDM [19],
or after an exercise training program in one patient with
JDM [16], as well as in a number of adult patients with
dermatomyositis [17].
While there is limited evidence to support the role of
exercise training in the management of patients with
JDM, definitive evidence is still lacking. In fact, to our
knowledge, no randomized controlled trials (RCT) of ex-
ercise training in JDM have been performed, which may
be secondary to limited patient availability and other
feasibility issues.
As such, we designed a RCT to study the feasibility of
an individually tailored 12-week home-based exercise
training program, and to assess its efficacy in children
and adolescents with JDM. The wash-out effects of this
program after another 12 weeks will also be examined.
Methods/design
Study design
The current study is a multi-center (4 sites) randomized
controlled trial, with the control group also entering the
training arm directly following completion of the initial
protocol. After randomization (1:1), subjects in both groups
will perform a test battery of exercise tests, questionnaires,
and other measurements (see study outcomes) (T0 meas-
urement). Thereafter, subjects in the intervention group will
receive an exercise training regimen, while the subjects in
the control group will continue to receive standard care
over a 12-week period. Subsequently, subjects in both
groups will repeat the battery of tests from T0 (T1 meas-
urement). Subjects in the intervention group will then
receive individual advice based on their T1 results and
educated on the physical activity guidelines for children
[20] in order to help maintain fitness levels following the
intervention. Subjects in the control group will enroll in the
exercise training program. Following this 12-week period,
subjects in both groups will repeat the battery of tests from
T0 and T1 (T2 measurement) and the subjects in the
control group will receive individual feedback in the same
manner as the intervention group at T1. After 12 weeks,
the subjects in the control group will repeat the battery of
tests from T0, T1, and T2 (T3 measurement). See Figure 1
for a flow diagram of the study design.
Subjects
All patients diagnosed with JDM by a pediatric
rheumatologist/immunologist according to the Bohan
and Peter criteria between the ages of 8 and 18 years
from 4 outpatient clinics in the Netherlands will be
Figure 1 Flow diagram of the study design.
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the Wilhelmina Children’s Hospital University Medical
Center (UMC) in Utrecht, the Beatrix Children’s Hospital
UMC in Groningen, the Sophia Children’s Hospital Eras-
mus Medical Center in Rotterdam, and the St. Radboud
Children’s Hospital UMC in Nijmegen.
Patients will be excluded for eligibility upon (1) a
medical status that contraindicates any form of exercise
testing; (2) an insufficient understanding of the Dutch lan-
guage in the patient and/or the parents/caregivers; (3) the
presence of medical events that might intervene with the
outcome of testing and/or the trial (such as a planned
operation) and/or (4) a negative advise from the rheuma-
tologist and/or physiotherapist based on resent relapse or
no limitations in exercise tolerance (in other words: the
patient was either not good enough or too good). All
eligible patients will be asked to participate in the study.
All parents/caregivers as well as subjects >12 years of age
years must provide informed consent before enrolment in
this study, which is approved by the Medical Ethics
Committee of the UMC Utrecht, the Netherlands.
The flow of the subjects in the study will be depicted
in the CONSORT Flowchart format [21]. The reasons
for non-eligibility, declination to participate, and non-
completion of the study will be reported in this flow-
chart as well.
Exercise training program
The intervention comprises of an individually tailored
12-week home-based exercise training program, combininginterval training on the treadmill (DKN Technology,
T210, Belgium) with strength training. Both types of
training are selected based on recommendations for
patients with chronic conditions [22], as well as to
specifically target the impaired exercise capacity and
muscle strength observed in patients with JDM. The
home-based nature of the intervention is selected to
minimize the burden and costs associated with travel
for both the patients and their parents. The training
program is divided in 3 phases of 4 weeks each as
shown in Table 1. Concerning the FITT factors
(frequency, intensity, time, and type) [23] and additional
parameters, the following selections are made.Type – interval training on treadmill
The aim of the interval training is to improve the
aerobic exercise capacity as it has previously been shown
to increase peak oxygen uptake in healthy children and
adolescents [24]. Moreover, compared with prolonged
continuous training, the short intermittent nature of
the exercise better simulates natural physical activities
of children [25] and it is more likely to be perceived as
enjoyable in a pediatric population. During the progres-
sion of the exercise training program, the intensity of
the intervals will increase simultaneously with a
decrease in the duration of each bout. The interval
training will be performed on the treadmill since
walking and running correspond closely to activities of
daily living that may be impaired in patients with JDM.
Table 1 Description of the exercise training program
Phase 1 2 3
Aim - Familiarizing the patient with
the treadmill
- Improving aerobic exercise
capacity
- Improving aerobic exercise as in
phase 2 albeit with a higher intensity
- Improving muscle strength - Improving muscle strength
as in phase 2
- Improving aerobic exercise capacity
- Developing proper strength training
techniques
Frequency [week-1] 3 3 2
Time/session [minutes] 40-60 45-60 50-60
Type Light interval training on
treadmill and strength training.
Moderate interval training on
treadmill and strength training.
Vigorous interval training on
treadmill and strength training.
Interval training on treadmill
Intensity [HR as % of HRpeak] 65-70 70-80 80-90
Interval duration [minutes] 3 2-2.5 1-2
Number of intervals 4-7 6-10 10-12
Strength training
Number of exercises 3 3 3
Number of sets/exercise 3 3 3
Number of repetitions
or time/set
Week 1: 3 repetitions As much repetitions in 20 or
30 seconds.
As much repetitions in 20 or
30 seconds.
Week 2–12: as much repetitions
in 20 or 30 seconds.
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The aim of the strength training program is to improve
the muscle strength of proximal muscle groups, since
these tend to be most affected in JDM. Along with the
recommendation that strength training in youth should
include large muscle groups [3], the following 3 exercises
are included: squat, abdominal crunch, and push-up. To
prevent muscle damage, the exercises are concentric in
nature and against gravity (no additional weight lifting).
A ball is implemented in some of the exercises to main-
tain the playfulness of the exercise.
Interval training on the treadmill and strength training
will be performed in an alternating fashion during each
session.Frequency
In order to improve aerobic exercise capacity and
muscle strength in children and adolescents, a training
frequency of 3-4 [24] and 2-3 [24,26] times per week,
respectively, is recommended. By taking these guide-
lines into account, as well as the time requirement for
the patient and parents to complete the session, the
training frequency during phase 1 and 2 is set at 3
sessions per week and it is reduced to 2 times per
week during phase 3 together with an increase in both
intensity and session duration. Consequently, the total
training program consists of 32 training sessions. Sub-
jects will be instructed to perform these sessions on
non-consecutive days.Intensity – interval training on treadmill
It is important that the intensity of the exercise training
is similar in all subjects [24]. Because of the large inter-
individual variability in peak heart rate (HRpeak) among
children [24], the intensity of the treadmill training in
the current study will be defined by HR as percentage of
HRpeak, which will be assessed prior to training at T0
(intervention group) or T1 (control group). In this way,
the standardization of the intervention is guaranteed.
Baquet et al. [24] state that training at a HR> 80% of
HRpeak may be essential in order to improve aerobic
exercise capacity in healthy children and adolescents.
However, this threshold intensity is likely to be reduced
for most deconditioned patiens with a chronic condition.
Durstine et al. [22] suggested a training intensity with an
oxygen uptake of 10-60% of peak oxygen uptake in these
chronic patients, which corresponds to approximately a
HR of about 66% of HRpeak [27]. Taking these guidelines
into account, exercise intensity in the current training
program will begin at a HR of 65% of HRpeak and
increase to a HR of 90% of HRpeak by the end of the
program. Further, periods of high intensity exercise (3–
1 minutes at HR of 65-90% of HRpeak) will alternate
with short periods of low intensity exercise (1 minute at
a HR of 50-60% of HRpeak).
The intensity of the intervals is ascertained in advance
(see Table 1) and it is constant for intervals during a sin-
gle training session. The initial gradient of the treadmill
during the intervals is set at 0% for each subject. The
speed will be adjusted individually in such a way that the
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This combination of gradient and speed is called level 1.
In total, 24 levels are formulated in which the next level
is either characterized by an increase in speed (alternately
0.6 and 0.4 kmh-1) or an increase in gradient of 1%.
During the intervals, subjects and parents will monitor
their HR using a heart rate monitor (DKN Technology,
Belgium). If HR does not fall within the predefined train-
ing range, the intensity of the next training session will
be increased or decreased by 1 level so as to maintain
the proper intensity.
Intensity - strength training
For strength training in healthy children and adoles-
cents, 1–3 sets of 6–15 repetitions are recommended
[26,28]. In the current training program, each of the 3
exercises consists of 3 sets. During the first week, only 3
repetitions are prescribed per set so as to ensure the
subjects develops proper strength exercise techniques
[26]. Over the course of the subsequent 11 weeks, the
intensity of the strength training is set by time. Squats
will be performed for 30 s per set and both the abdom-
inal crunches and push-ups will be performed for 20 s
per set. All exercises have 2 possible extensions in which
the exercise load becomes heavier and more challenging.
An extension will be prescribed when the subject shows
proper techniques and describes the exercise as light or
easy.
Subjects will be given a 1 min rest period between sets
according to the recommendations of Faigenbaum et al.
[26]. Such a short period allows for the development of
muscular endurance [29], which is highly desired in this
patient group.
Time and duration
The total time per session, which includes treadmill
training, strength training, warming-up, cooling-down,
and rest periods, is 40–60 minutes. Each session consists
of 15–25 minutes at or above the threshold intensity, as
recommended by Takken et al. [23] The program dur-
ation is set at 12 weeks according to the recommenda-
tions for exercise training in children with chronic
conditions [30].
Warming-up and cooling-down
Each exercise session starts and ends with a 5-min dur-
ing low intensity walk on the treadmill at a HR of 50-60
% of HRpeak [26].
Supervision
Each subject will receive a detailed and individualized
description of the exercise program and will be asked to
keep track of every completed stage. Parents will be
asked to be present at each training session to providetheir child with support and motivation, to ensure
proper strength training techniques, as well as to assist
them with the use of the treadmill and the HR monitor.
Furthermore, the subjects will be asked to keep a day-
to-day journal for training compliance. Every 2 weeks, a
researcher or physiotherapist will conduct a home visit
to observe the training session, to ensure compliance, to
motivate the subject, as well as to make adjustments to
the training prescription as needed.Randomization and blinding
Included subjects will be stratified according to age (≤ or
>12 years) and gender after which they will be rando-
mized to either the intervention or the control group.
The randomization process will be performed by a per-
son with no clinical involvement in the trial. Blocking is
used to ensure close balance of the numbers in each
group at any time during the trial. Randomly varying the
block size (2 or 4) reserves the unpredictability of the se-
quence. The sequences will be concealed until interven-
tions are assigned. The researchers performing the
assessments, as well as those charged with data analyzes
will be blinded to treatment allocation.Baseline description of groups
The baseline descriptors of the groups are age, gender,
anthropometrics and disease characteristics. The an-
thropometrics include maturity offset (years), height
(M), body mass (kg), body mass index (kgm-2), and fat
free mass (kg). The disease characteristics include age at
diagnosis (years), disease duration at inclusion (years),
disease course (monocyclic/ polycyclic/ chronic), and
medication usage. These descriptors will be compared
between the treatment group and the control group at
T0. Maturity offset will be determined with gender-
specific equations including chronological age, height,
body mass, and sitting height [31]. Fat free mass will be
measured with BODYSTATW QuadScan 4000. Disease
duration at inclusion will be defined as the time from
diagnosis to inclusion. Disease course will be classified
as monocyclic (no signs of disease activity 2 years after
diagnosis), polycyclic (recurrence of active disease after a
definite remission (>6 months), followed by one or
more flares), or chronic (persistent disease activity
>2 years after diagnosis)[32].Study outcomes
Efficacy
The primary and secondary efficacy outcome measures
along with the tools for these assessments are described
below and in Table 2.
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Aerobic exercise capacity will be measured with a
treadmill-based (RAM, Accuramed BVBA, Lummen,
Belgium) incremental maximal exercise test according
the protocol set out by the German Society for Pediatric
Cardiology [33]. Briefly, the test starts at a speed of
2 kmh-1 with a 0% grade; the speed increases by 0.5 kmh-1
and the grade by 3%, up to a maximum of 21%, every 90 s.
The test is terminated upon voluntary exhaustion, despite
strong verbal encouragement.
Throughout the test, the subject will wear a facemask
(Hans Rudolph Inc, Kansas City, MO) connected to a gas
analysis system (ZAN 600, Accuramed BVBA, Lummen,
Belgium), which will allow for a sample of expired gases to
pass to a flowmeter, an oxygen analyzer, and a carbon
dioxide analyzer. Volume calibration and gas analysis
calibration will be performed before each testing ses-
sion. The flow meter and gas analyzers are connected
to a computer that calculate breath-by-breath minute
ventilation (VE), oxygen uptake (VO2), carbon dioxide
output (VCO2), and the respiratory exchange ratio
(RER=VCO2/VO2) using conventional equations. HR
will be measured continuously via a 12-lead electrocar-
diogram (CardioPerfect, IT medical, the Netherlands).
The test will be deemed maximal when the HR is >180
beatsmin-1 and/or the RER >1.0.
The outcome measures related to aerobic exercise cap-
acity that will be assessed include: VO2peak [lmin-1]: the
average volume of the absolute oxygen uptake during the
last 30-s period of the test; VO2peak/kg [mlkg-1min-1]: the
absolute VO2peak divided by body mass. This variable was
used for the power calculation; VO2VAT [lmin-1]: the
absolute VO2 eliciting the ventilatory anaerobic threshold
(VAT). The VAT will be determined as defined by an
increase in both the ventilatory equivalent of oxygen
(=VE/VO2) and end-tidal pressure of oxygen with no
concurrent increase in the ventilatory equivalent of
carbon dioxide (=VE/VCO2); VO2VAT/kg [mlkg-1min-1]:
the absolute VO2VAT divided by body mass; O2 pulse
[mlbeat-1]; and endurance time [min]: the time from the
start to the end of the protocol.
Isometric muscle strength of the proximal muscle
groups in the lower extremities will be measured on
both the right and left sides with a calibrated CITEC
hand-held dynamometer (C.I.T. Technics, Groningen, the
Netherlands). Both the extensors of the knee joint and the
flexors of the hip joint will be assessed with 3 consecutive
measurements according to the ‘break method’, wherein
the examiner gradually overcomes the muscle force and
stops at the moment the extremity gives way [34]. The
highest value of the 3 repetitions will be recorded. All
within-subject tests will be performed by the same asses-
sor using the same hand-held dynamometer to prevent
inter-observer and inter-instrument bias [34].Perception of fatigue will be measured with the Dutch
translated PedsQL Multidimensional Fatigue Scale. This
scale, designed to measure fatigue in pediatric patients,
reflects 3 subscales: general fatigue, sleep/rest fatigue,
and cognitive fatigue [35-37].
Secondary outcome measures
Muscle soreness will be measured using a 10-cm Visual
Analogue Scale (VAS). Muscle function will be assessed
via Subscale 8 (Strength) of the Bruininks-Osteretsky
Test of Motor Proficiency, Second Edition (BOT-2),
which include 5 items that are related to the strength
training program of the subjects [38]. The Childhood
Myositis Assessment Scale (CMAS) is specially designed
to assess the functional consequences of proximal
muscle strength and endurance, and will also be utilized
as a marker of muscle function in our subjects [39].
Functional sub maximal aerobic exercise capacity will be
assessed by examining walking distance at the 6-min
walk test (6MWT) [40]. This will be followed by an as-
sessment of physical activity enjoyment using the Phys-
ical Activity Enjoyment Scale (PACES) [41]. Quality of
life will be measured with the patient form of the Dutch
translated PedsQL Generic Core Scale [36,42,43]. Func-
tional ability will be measured with the Childhood
Health Assessment Questionnaire (CHAQ), a disease
specific questionnaire that measures the grade of disabil-
ity in performing activities of daily living as observed by
the parents [44-46]. The VAS discomfort items of the
CHAQ will be filled in by the subjects. Finally, habitual
levels of physical activity will be monitored via accelero-
metry (Actical) [47] and a Bouchard activity journal
[48,49] over a 7 day period.
Power calculation
A power calculation was performed based on previously
published data relating to one of the primary outcome
measures: VO2peak/kg. The mean ± standard deviation
VO2peak/kg of patients with JDM (in remission) is
33 ± 8 mlkg-1min-1 [13]. The aim of this training inter-
vention is to improve VO2peak/kg by at least 22%, which
is the weighted mean improvement in exercise training
studies in adults with inflammatory myositis [17]. Given
an 80% probability of detecting a treatment effect, with
significance set at 0.05 (two-tailed), the required number
of total subjects is 22; 11 in each of the 2 groups. Upon
factoring in a 20% (n= 5) chance of missing observations
and/or drop-outs, the total sample size increase to 27
patients. For simplicity in the randomization process, we
want to include 30 patients.
Statistical analysis
Data will be checked for normal distribution. Three dif-
ferent types of analysis will be performed.
Table 2 The primary and secondary study outcomes and the accompanying measurement tools used
Items Range +/−
Aerobic exercise capacity (Maximal exercise test on treadmill)
VO2peak [lmin-1] na >0 +
VO2peak/kg [mlkg-1min-1] 1 na >0 +
O2 pulse [mlbeat-1] na >0 +
Endurance time [min] na >0 +
VO2VAT [lmin-1] na >0 +
VO2VAT/kg [mlkg-1min-1] na >0 +
Isometric muscle strength (Hand-held dynamometry – Break method)
Maximal force right knee extensors [N] na >0 +
Maximal force left knee extensors [N] na >0 +
Maximal force right hip flexors [N] na >0 +
Maximal force left hip flexors [N] na >0 +
Perception of fatigue (PedsQL Multidimensional Fatigue Scale – patient form)
Total score 18 0-100 +
Subscale General Fatigue score 6 0-100 +
Subscale Sleep/Rest Fatigue score 6 0-100 +
Subscale Cognitive Fatigue score 6 0-100 +
Muscle soreness (10-cm Visual Analogue Scale muscle soreness)
Visual Analogue Scale muscle soreness [cm] na 0-10 -
Muscle function (BOT-2 Subscale 8 – Strength)
Total score 5 0-42 +
Item Distance standing long jump [m] na >0 +
Item Amount of sit-ups in 30 s na ≥0 +
Item Amount of push-ups in 30 s na ≥0 +
Item Time wall sit [s] na 0-60 +
Item Time V-up [s] na 0-60 +
Muscle function (Childhood Myositis Assessment Scale)
Total score 14 0-52 +
Functional sub maximal aerobic exercise capacity (6-Minute Walk Test)
Distance [m] na >0 +
Physical activity enjoyment (Physical Activity Enjoyment Scale)
Total score 17 17-119 +
Quality of life (PedsQL Generic Core Scale – patient form)
Total score 23 0-100 +
Subscale Physical Functioning score 8 0-100 +
Subscale Emotional Functioning score 5 0-100 +
Subscale Social Functional score 5 0-100 +
Subscale School Functioning score 5 0-100 +
Functional ability (Childhood Health Assessment Questionnaire 30 + 8)
Subscale Dressing score 4 0-3 -
Subscale Arising score 2 0-3 -
Subscale Eating score 3 0-3 -
Subscale Walking score 2 0-3 -
Subscale Hygiene score 5 0-3 -
Subscale Reach score 4 0-3 -
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Table 2 The primary and secondary study outcomes and the accompanying measurement tools used (Continued)
Subscale Grip score 5 0-3 -
Subscale Activities score 5 0-3 -
Subscale School/Extracurricular score 8 0-3 -
Disability score [%] 38 0-100 -
Visual Analogue Scale pain [cm] na 0-10 -
Visual Analogue Scale global disease severity [cm] na 0-10 -
Physical activity (Actical accelerometer for 7 days)
na >0 +
Physical activity (Activity journal for 2 weekdays + 1 Saturday)
Time inactive [%] na 0-100 -
Time light active [%] na 0-100 −/+
Time moderate active [%] na 0-100 −/+
Time vigorous active [%] na 0-100 +
Abbreviation: na: not applicable.
1 the primary outcome measure on which power calculation was performed.
+: an increase in value denotes an improvement -: a decrease in value denotes an improvement.
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To examine the efficacy of the intervention, the outcome
measures of the intervention group and control group
will be compared at each of time points T0 and T1 using
mixed linear regression analysis with group (intervention/
control) as independent variable and the outcome mea-
sures (see Table 2) as separate dependent variables.Intervention in control group
To examine the efficacy of the intervention in the con-
trol group, changes in outcome measures between T0
and T1 (usual care) will be compared with the changes
in outcome measures between T1 and T2 (intervention)
using a paired samples T-test.“Wash-out” effect in intervention and control group
Repeated measures ANOVA analyzes will be performed
to examine whether the effects of the intervention are
maintained after 12 weeks. Specifically, the outcome
measures of both groups will be compared between
post-12-week usual care after intervention vs. post-
intervention and post-12-week usual care after interven-
tion vs. pre-intervention.
Results will be presented as linear regression coeffi-
cients representing mean group differences with their
corresponding 95% confidence intervals (CI). Statistical
significance will be defined as cases in which the 95% CI
does not include the null value. Nominal variables will
be analyzed using chi-square analysis. All results will be
analyzed using the modified intention to treat approach
which means that all subjects will be included in the
groups to which they are randomized, and the researchersmake efforts to obtain outcome data for all subjects, even
if they do not complete the full intervention [50].
Feasibility
Feasibility will be assessed by examining the amount of
training sessions each subject performed during the
intervention. Every week, the subject has to start the ex-
ercise training program of a new week, independent
whether the proposed amount of training sessions of the
previous week is reached. When the subject is not able
to train for at least 7 consecutive days (e.g. due to illness
or holiday), the subject will be asked to resume the exer-
cise training program where he/she was ended.
Discussion
This paper presents the design of a randomized con-
trolled study that will provide evidence on the efficacy
and feasibility of an individually tailored 12-week home-
based exercise training program for children and adoles-
cents with JDM. The wash-out effects of this program
after another 12 weeks will also be examined.
Among the many strength of this study is first, the fact
that this will be the first RCT to assess the effects of exer-
cise training in patients with JDM. Second, evidence from
literature is used to design the treadmill training as well as
the strength training program. Third, the focus of the
intervention, as well as the primary outcome measures,
corresponds to the major clinical concerns of patients
with JDM. Finally, and perhaps most importantly, the
intervention is a home-based program, which minimizes
the load for the patients and their parents while likely
stimulating the patient’s desire and motivation to continue
exercising upon completion of the intervention.
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